Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China OTC Drug Sales Pummeled By Pseudoephedrine Restrictions

This article was originally published in The Tan Sheet

Executive Summary

Multinational cold and cough OTC products have suffered a serious setback in China, as government restricts usage of drugs containing pseudoephedrine.

Advertisement

Related Content

Game Of Thrones: Bayer Looks To Lead China’s OTC Market
Game Of Thrones: Bayer Looks To Lead China’s OTC Market
Dihon Acquisition Doubles Bayer’s Consumer Health Presence In China
Dihon Acquisition Doubles Bayer’s Consumer Health Presence In China
J&J Creates ONE China OTC As Country’s Largest Consumer Health Firm
J&J Creates ONE China OTC As Country’s Largest Consumer Health Firm
Sales & Earnings In Brief
Bayer Increases Chinese Presence With Topsun Cough/Cold Buy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS106583

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel